Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | SPH4336 |
| Synonyms | |
| Therapy Description |
SPH4336 inhibits CDK4 and CDK6, which potentially induces antitumor activity (J Clin Oncol 42, 2024 (suppl 16; abstr e15107)). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| SPH4336 | SPH 4336|SPH-4336 | CDK4/6 Inhibitor 14 | SPH4336 inhibits CDK4 and CDK6, which potentially induces antitumor activity (J Clin Oncol 42, 2024 (suppl 16; abstr e15107)). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05580588 | Phase II | SPH4336 | Open-Label Study of the CDK4/6 Inhibitor SPH4336 in Subjects With Locally Advanced or Metastatic Liposarcomas | Terminated | USA | 0 |